Get the Stockscreener App
26.25
1.83%
-0.49
Pre-market:
26.60
0.35
+1.33%
Moderna Inc stock is traded at $26.25, with a volume of 7.03M.
It is down -1.83% in the last 24 hours and up +11.65% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.74
Open:
$26.32
24h Volume:
7.03M
Relative Volume:
0.71
Market Cap:
$10.21B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.0069
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-3.99%
1M Performance:
+11.65%
6M Performance:
-2.05%
1Y Performance:
-54.53%
1-Day Range:
$26.01
$26.69
1-Week Range:
$26.01
$29.45
52-Week Range:
$23.15
$58.62
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.25 | 10.40B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Moderna: Q3 Earnings PreviewI Fear A Halloween Horror Show (Downgrade) (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks - GuruFocus
How to use Fibonacci retracement on Moderna Inc.July 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Key facts: Moderna faces cash flow challenges; stock rises on therapy data - TradingView
Moderna (MRNA) Stock Trades Up, Here Is Why - The Globe and Mail
Moderna’s Off-The-Shelf Cancer Immunotherapy Shows Early Promise - insights.citeline.com
Is Moderna Inc. meeting your algorithmic filter criteriaRate Hike & Fast Exit Strategy with Risk Control - newser.com
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Benzinga
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment - GuruFocus
What’s next for Moderna Inc. stock priceJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Moderna (MRNA) Tops Healthcare Short Interest Rankings - GuruFocus
Intraday pattern recognizer results for Moderna Inc.2025 Volume Leaders & AI Driven Stock Movement Reports - newser.com
Respiratory Syncytial Virus (RSV) Market Explosion To hit - openPR.com
Moderna Claims Early Victory for Cancer Antigen in Melanoma - BioSpace
Moderna, Inc. (MRNA) Stock Analysis: Navigating Volatility With A 65% Potential Upside - DirectorsTalk Interviews
Moderna reports early cancer therapy data at medical conference - StreetInsider
KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC - MarketBeat
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress - Times Herald
Moderna says it presents promising early data for investigational cancer antigen therapy - MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Shreveport Times
Moderna (NASDAQ:MRNA) Given New $32.00 Price Target at Morgan Stanley - MarketBeat
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Monroe Evening News
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - TradingView
MRNA: Morgan Stanley Raises Price Target for Moderna | MRNA Stock News - GuruFocus
Covid-19 Vaccine Recommendations | Moderna - OurQuadCities
Moderna assists with the evolving landscape of COVID-19 vaccine - KHGI
AstraZeneca ups investment in Virginia; Moderna vets launch VC fund - BioPharma Dive
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Newport Daily News
Should Moderna's (MRNA) Improved Revenue Trends Prompt New Action From Investors? - Yahoo Finance
Is Moderna Inc. trending in predictive chart modelsRate Hike & Daily Stock Trend Reports - newser.com
Moderna, Inc. $MRNA Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Best Biotech Stocks To Follow NowOctober 6th - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
GSK Doesn't Have To Explain COVID Vax Claims For Moderna - Law360
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Updated COVID shot led to less severe illness, fewer hospitalizations last year, US study finds - MarketScreener
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further? - ts2.tech
Moderna, Inc. (MRNA): Among the Best Vaccine Stocks to Buy According to Hedge Funds - MSN
Moderna (MRNA) COVID-19 Booster Recommendations Updated by CDC - GuruFocus
CDC adopts individual-based decision-making for COVID-19 shots (MRNA:NASDAQ) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna - WCIV
Moderna (MRNA): Assessing Valuation After Recent 12% Share Price Jump and Updated Financials - Yahoo Finance
Will Moderna Inc. see short term momentum2025 Year in Review & Fast Moving Stock Trade Plans - newser.com
Key metrics from Moderna Inc.’s quarterly data2025 EndofYear Setup & Step-by-Step Swing Trade Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 16% Return (vs. -31% YTD) [10/3/2025] - Trefis
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Greenville Online
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):